Beta Bionics (BBNX) closed at $21.39 on Oct 27, 2026, up 4.3% on the day. The stock is up 4.2% over the past month, up 41.0% over three months, down 29.8% year to date and up 2.1% over the past year. It trades 34.6% below its 52-week high of $32.71 and 143.1% above its 52-week low of $8.80. The close sits above its 50-day moving average ($19.23) and above its 200-day moving average ($14.82).
Yes — the Oct 27, 2026 close of $21.39 is 44.4% above the 200-day average of $14.82.
BBNX closed 34.6% below its 52-week high of $32.71.
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is headquartered in Irvine, California.
